MiR-142-3p functions as an oncogene in prostate cancer by targeting FOXO1

Yi-Fan Tan, Zhiyuan Chen, Lei Wang, Min Wang, Xiuheng LiuJournal of Cancer 2020 · DOI

TL;DR

This study reveals that a microRNA, miR-142-3p, acts as an oncogene in prostate cancer (PCa) by suppressing the tumor-suppressive protein FOXO1. By identifying this regulatory axis, the research proposes miR-142-3p as a potential therapeutic target for PCa.

What Problem Does This Paper Address?

Prostate cancer (PCa) remains a significant cause of cancer-related mortality in men. While Forkhead box transcription factor O1 (FOXO1) is known to have anti-tumor effects in various cancers, including PCa, the precise mechanisms regulating its expression and function in PCa have not been fully elucidated. Specifically, the role of microRNAs (miRNAs) in controlling FOXO1 levels and their subsequent impact on PCa progression were unclear. This paper aims to characterize the regulatory relationship between miR-142-3p and FOXO1 in PCa and to understand how this interaction influences cancer development.

Methods

The researchers employed a multi-pronged approach to investigate the miR-142-3p/FOXO1 axis in PCa:

  • Bioinformatics Analysis: They utilized the GEPIA 2 database to assess FOXO1 expression across various cancer types and specifically in PCa tissues compared to normal tissues. The StarBase database was used to examine miR-142-3p expression in PCa and to predict potential miRNA targets.
  • Tissue and Cell Line Analysis: They analyzed patient-derived PCa specimens and paired normal tissues, as well as established PCa cell lines (PC3, DU145, LNCAP) and a normal prostate epithelial cell line (RWPE1).
  • Molecular Techniques:
    • Western Blotting and RT-qPCR: Used to quantify protein and mRNA levels of FOXO1 and miR-142-3p, respectively, in tissues and cell lines, and to assess the efficacy of transfection.
  • Immunohistochemistry: Employed to visualize FOXO1 protein expression in tissue sections.
  • Cell Proliferation Assays (CCK-8): To measure the impact of genetic manipulations on cancer cell growth.
  • Flow Cytometry: Used to analyze cell cycle progression and identify cell cycle arrest.
  • Luciferase Reporter Assay: A key technique to confirm direct targeting of FOXO1's 3'-untranslated region (3'UTR) by miR-142-3p.
  • RNA Interference (siRNA) and Plasmid Transfection: To upregulate or downregulate the expression of FOXO1 and miR-142-3p in cell lines.
  • In Vivo Studies: Xenograft mouse models were used to evaluate the effect of miR-142-3p knockdown on tumor growth.

Datasets

  • GEPIA 2 Database: Used for analyzing gene expression data from The Cancer Genome Atlas (TCGA) across various cancer types and specifically for FOXO1 in PCa.
  • StarBase v3.0: Utilized for investigating miR-142-3p expression in PCa and for predicting miRNA-mRNA interactions.
  • Patient Samples: 20 PCa specimens with paired normal tissues were collected from patients who underwent prostatectomy.

Key Insights and Ideas

  • FOXO1 as a Tumor Suppressor in PCa: The study strongly supports FOXO1's role as a tumor suppressor in PCa, showing its downregulation in cancer tissues and cells, and linking low FOXO1 levels to poorer disease-free survival.
  • MiR-142-3p as an Oncogene: Conversely, miR-142-3p is identified as an oncogene, with its levels elevated in PCa and its suppression leading to reduced tumor growth.
  • Direct Targeting Mechanism: The crucial finding is the direct interaction between miR-142-3p and the 3'UTR of FOXO1 mRNA, establishing a clear molecular mechanism for how miR-142-3p represses FOXO1.
  • Discrepancy in FOXO1 mRNA vs. Protein: The observation that FOXO1 mRNA levels did not significantly differ between PCa and normal tissues, while protein levels were consistently downregulated, highlights the importance of post-transcriptional regulation (like miRNA activity) in controlling FOXO1's functional impact.
  • Therapeutic Potential: The identification of the miR-142-3p/FOXO1 axis as a key regulator in PCa progression opens avenues for developing targeted therapies.

Key Results

  • FOXO1 Downregulation: FOXO1 protein levels were significantly decreased in PCa tissues and cell lines compared to their normal counterparts. Low FOXO1 expression was associated with reduced disease-free survival and poorer prognosis.
  • FOXO1's Anti-Cancer Effects: Overexpression of FOXO1 suppressed PCa cell proliferation and induced G0/G1 cell cycle arrest in vitro. Conversely, FOXO1 knockdown promoted proliferation.
  • MiR-142-3p Upregulation: MiR-142-3p levels were significantly elevated in PCa tissues and cell lines.
  • Negative Correlation: MiR-142-3p expression was negatively correlated with FOXO1 protein levels in PCa.
  • Direct Targeting Confirmation: Luciferase reporter assays confirmed that miR-142-3p directly binds to the 3'UTR of FOXO1 mRNA, leading to its repression.
  • MiR-142-3p Promotes Proliferation: Overexpression of miR-142-3p promoted PCa cell proliferation and cell cycle progression, an effect that was blocked by restoring FOXO1 expression.
  • Inhibition of Tumor Growth in vivo: Knockdown of miR-142-3p in a xenograft mouse model significantly reduced tumor weight and volume, and increased FOXO1 expression within the tumors.

Limitations and Future Work

  • Mechanism of miR-142-3p Elevation: The paper notes that the mechanism by which miR-142-3p expression is elevated in human cancer remains to be fully characterized. This is a key area for future investigation.
  • Broader Clinical Relevance: While the study provides strong evidence in cell lines and mouse models, further validation in larger patient cohorts and diverse PCa subtypes would strengthen the clinical implications.
  • Therapeutic Strategy Development: The authors suggest that the miR-142-3p-FOXO1 axis is a potential therapeutic target. Future work would involve developing and testing specific inhibitors or modulators of this axis for PCa treatment.
  • Other Targets of miR-142-3p: While FOXO1 is identified as a direct target, it's possible miR-142-3p regulates other genes that contribute to PCa progression, which could be explored.

Summary updated

Abstract

Prostate cancer (PCa) is a heterogeneous malignancy, and is a primary cause of cancer-related death in males. Forkhead box transcription factor O1 (FOXO1) exerts antitumor effects in various cancers, including PCa. However, the regulatory mechanism of miR-142-3p on FOXO1 expression in human PCa has not been characterized. In this study, we showed that FOXO1 protein levels were downregulated in PCa tissues and cells. Moreover, FOXO1 expression was a predictor of disease-free survival in patients with PCa and was a predictor of prognosis. Increased expression of FOXO1 suppressed cellular proliferation and induced cell cycle arrest at G0/G1 <i>in vitro</i>. However, FOXO1 mRNA and protein levels were inconsistent in human PCa tissues and cell lines. We showed that miR-142-3p levels were negatively correlated with FOXO1 protein levels in PCa. We also showed that miR-142-3p suppressed FOXO1 expression by directly targeting its 3'-untranslated region. Furthermore, suppression of miR-142-3p inhibited cell proliferation and induced cell cycle arrest, and these effects were blocked by FOXO1 knockdown. <i>In vivo</i> experiments showed that miR-142-3p knockout impaired tumor growth. Our results validate that FOXO1 acted as a tumor suppressor in PCa and demonstrated that FOXO1 was regulated by miR-142-3p, and miR-142-3p may be a potential target for treatment of PCa.
BibTeX
@article{tan2020mir,
  author = {Yi-Fan Tan and Zhiyuan Chen and Lei Wang and Min Wang and Xiuheng Liu},
  title = {{MiR-142-3p functions as an oncogene in prostate cancer by targeting FOXO1}},
  journal = {Journal of Cancer},
  year = {2020},
  doi = {10.7150/jca.41888},
}
Figure